Patents by Inventor John Y. Park
John Y. Park has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8697671Abstract: Compositions comprising a glycosaminoglycan (e.g., a hyaluronan, hyaluronic acid, hyaluronate, sodium hyaluronate, dermatan sulfate, karatan sulfate, chondroitin 6-sulfate, heparin, etc.) in combination with at least one component selected from; i) polyglycols (e.g., polyethylene glycol), ii) long chain hydroxy polyanionic polysaccharides (e.g., dextran, sodium alginate, alginic acid, propylene glycol alginate, carboxymethyl cellulose and carboxyethyl cellulose, hydroxyl ethyl starch, hydroxyl propyl methyl cellulose, hydroxy propyl ethyl cellulose, hydroxy propyl cellulose, methyl cellulose, polylysine, polyhistidine, polyhydroxy proline, poly ornithine, polyvinyl pyrolidone, polyvinyl alcohol, chitosan, etc.) and iii) long chain Nitrogen containing polymers (e.g., Polylysine, Polyvinylpyrrolidone, and polyvinyl alcohol). The invention also includes methods for using such compositions (e.g., as substance delivery materials, tissue fillers or bulking agents, as moistening or hydrating agents, etc.).Type: GrantFiled: October 9, 2012Date of Patent: April 15, 2014Assignee: S.K. Pharmaceuticals, Inc.Inventors: Hampar L. Karageozian, John Y. Park
-
Publication number: 20130129621Abstract: Compounds comprising R-G-Cysteic Acid (i.e., R-G-NH—CH(CH2—SO3H)COOH or Arg-Gly-NH—CH(CH2—SO3H)COOH) and derivatives thereof, including pharmaceutically acceptable salts, hydrates, stereoisomers, multimers, cyclic forms, linear forms, drug-conjugates, pro-drugs and their derivatives. Also disclosed are methods for making and using such compounds including methods for inhibiting integrins including but not necessarily limited to ?5?1-Integrin, ?v?3-Integrin and ?v?5-Integrin, inhibiting cellular adhesion to RGD binding sites, preventing or treating viral or other microbial infections, inhibiting angiogenesis in tumors, retinal tissue or other tissues or delivering other diagnostic or therapeutic agents to RGD binding sites in human or animal subjects.Type: ApplicationFiled: May 9, 2012Publication date: May 23, 2013Applicant: ALLEGRO PHARMACEUTICALS, INC.Inventors: Michael John Mackel, John Y. Park, Hampar L. Karageozian, Vicken H. Karageozian
-
Publication number: 20030175259Abstract: An Enzyme Orthokeratology method is provided for correcting refractive errors in the eye of a subject mammal. Accelerating reshaping of the cornea is accomplished by administering a corneal hardening amount of a corneal hardening agent to the eye of the subject. Reformation is accomplished under the influence of a rigid contact lens or a series of lenses having a concave curvature that will correct a refractive error. The cornea rapidly reshapes its convex curvature to the concave curvature of the contact lens, rendering the eye emmetropic. The cornea is permitted to “harden” to retain the new emmetropic shape. After “hardening” has occurred, the lens rendering the eye emmetropic is removed.Type: ApplicationFiled: December 12, 2002Publication date: September 18, 2003Inventors: Hamper Karageozian, John Y. Park, Vicken Karageozian, Phillip Baker, Anthony Nesburn
-
Patent number: 6537545Abstract: An Enzyme Orthokeratology method is provided for correcting refractive errors in the eye of a subject mammal. Accelerating reshaping of the cornea is accomplished by administering a corneal hardening amount of a corneal hardening agent to the eye of the subject. Reformation is accomplished under the influence of a rigid contact lens or a series of lenses having a concave curvature that will correct a refractive error. The cornea rapidly reshapes its convex curvature to the concave curvature of the contact lens, rendering the eye emmetropic. The cornea is permitted to “harden” to retain the new emmetropic shape. After “hardening” has occurred, the lens rendering the eye emmetropic is removed.Type: GrantFiled: September 7, 2000Date of Patent: March 25, 2003Assignee: ISTA Pharmaceuticals, Inc.Inventors: Hamper Karageozian, John Y. Park, Vicken Karageozian, Phillip Baker, Anthony Nesburn
-
Patent number: 6136850Abstract: Methods and compositions for inhibiting the formation of proteinaceous and/or lipid deposits on a contact lens are disclosed. In one embodiment, the present method comprises contacting a contact lens being worn in a mammalian eye with at least one ophthalmically acceptable antioxidant component in an amount effective to inhibit the formation of at least one of proteinaceous deposits and lipid deposits on the contact lens in the eye.Type: GrantFiled: February 12, 1993Date of Patent: October 24, 2000Assignee: AllerganInventors: John Y. Park, James N. Cook, Dorla Mirejovsky, Steven S. Matsumoto
-
Patent number: 6024954Abstract: Compositions for disinfecting contact lenses include a liquid medium containing a chlorite component, preferably a water soluble chlorite component, in a contact lens disinfecting amount, and a polyanionic component, preferably a water soluble polyanionic component, in an amount effective to do at least one of the following: inhibit formation of protein deposit material on a contact lens immersed in the composition; reduce the toxicity of the composition to the human eye, and reduce the damage to a contact lens caused by immersing the contact lens in the composition. The composition has a viscosity of less than 50 cps at 25.degree. C., an osmolality of at least about 200 mOsmol/kg, and preferably a pH in the range of about 6 to about 9.Type: GrantFiled: August 2, 1996Date of Patent: February 15, 2000Assignee: AllerganInventors: John Y. Park, Lin Peng, Daniel P. Cafaro, Anthony J. Dziabo
-
Patent number: 5989847Abstract: A composition and method useful to quickly and effectively indicate whether a functional component such as catalase has been added to a clear solution such as a hydrogen peroxide solution involves compounding with the functional component an effective amount of vitamin B-12 such that when the compounded composition is added to the clear solution, the clear solution turns rose colored. By observing the rose color, the user can determine that the functional component has been added to the clear solution.Type: GrantFiled: October 30, 1996Date of Patent: November 23, 1999Assignee: AllerganInventors: John Y. Park, James N. Cook, Anthony J. Dziabo, Jr.
-
Patent number: 5882687Abstract: Compositions for storing contact lenses include a liquid medium containing a polyanionic component, preferably a water soluble polyanionic component, in an amount effective to provide a hydration layer on the surface of said contact lens. The composition has a viscosity of less than 50 cps at 25.degree. C., an osmolality of at least about 200 mOsm/kg, and preferably a pH in the range of about 6 to about 9.Type: GrantFiled: January 10, 1997Date of Patent: March 16, 1999Assignee: AllerganInventors: John Y. Park, Daniel Cafaro, Anthony J. Dziabo
-
Patent number: 5840250Abstract: Compositions and methods useful for disinfecting a contact lens are disclosed. The present methods comprise contacting a contact lens with a liquid medium containing an effective amount of an oxidative disinfectant component at conditions to effectively disinfect the contact lens. The contacting occurs in the presence of a color indicator component which is soluble in the liquid medium and is adapted to provide a color indication of the presence of the oxidative disinfectant component in the liquid medium. The color indicator component comprises an effective amount of a transition metal component which is redox active, has an oxidized state of a first color and a reduced state of a different second color and a polyanionic component in an amount effective to inhibit the staining of the contact lens by the transition metal component.Type: GrantFiled: September 30, 1997Date of Patent: November 24, 1998Assignee: AllerganInventors: John Y. Park, Lin Peng, Anthony J. Dziabo
-
Patent number: 5746972Abstract: Compositions and methods for disinfecting and cleaning contact lenses include a liquid medium containing hydrogen peroxide and a defined ethylene oxide/propylene oxide block copolymer. An advantageously reduced amount of foaming occurs when the hydrogen peroxide is destroyed, particularly by the action of catalase.Type: GrantFiled: November 1, 1996Date of Patent: May 5, 1998Assignee: AllerganInventors: John Y. Park, Larry K. Thomas, Lin Peng, Daniel P. Cafaro
-
Patent number: 5703024Abstract: Compositions and methods useful for disinfecting a contact lens are disclosed. The present methods comprise contacting a contact lens with a liquid medium containing an effective amount of an oxidative disinfectant component at conditions to effectively disinfect the contact lens. The contacting occurs in the presence of a color indicator component which is soluble in the liquid medium and is adapted to provide a color indication of the presence of the oxidative disinfectant component in the liquid medium. The color indicator component comprises an effective amount of a transition metal component which is redox active, has an oxidized state of a first color and a reduced state of a different second color and a polyanionic component in an amount effective to inhibit the staining of the contact lens by the transition metal component.Type: GrantFiled: June 30, 1995Date of Patent: December 30, 1997Assignee: AllerganInventors: John Y. Park, Lin Peng, Anthony J. Dziabo
-
Patent number: 5681591Abstract: A composition useful for disinfecting a contact lens comprising a substantially isotonic, aqueous liquid medium containing hydrogen peroxide in an amount effective to disinfect a contact lens contacted with the aqueous liquid medium, and a hydrogen peroxide reducing agent dissolved in the aqueous liquid medium in an amount effective to enhance the antimicrobial activity of the aqueous liquid medium. Preferably, the composition further includes transition metal ions in an amount effective to further enhance the antimicrobial activity of the aqueous liquid medium and is substantially free of peroxidase.Type: GrantFiled: September 17, 1992Date of Patent: October 28, 1997Assignee: AllerganInventors: John Y. Park, James N. Cook, Claude B. Anger
-
Patent number: 5660862Abstract: A composition useful for disinfecting a contact lens comprising a substantially isotonic, aqueous liquid medium containing hydrogen peroxide in an amount effective to disinfect a contact lens contacted with the aqueous liquid medium, and a hydrogen peroxide reducing agent dissolved in the aqueous liquid medium in an amount effective to enhance the antimicrobial activity of the aqueous liquid medium. Preferably, the composition further includes transition metal ions in an amount effective to further enhance the antimicrobial activity of the aqueous liquid medium and is substantially free of peroxidase.Type: GrantFiled: May 24, 1995Date of Patent: August 26, 1997Assignee: AllerganInventors: John Y. Park, James N. Cook, Claude B. Anger
-
Patent number: 5648074Abstract: Compositions and methods for disinfecting contact lenses are disclosed. In one embodiment, the present compositions include a liquid medium containing chlorine dioxide precursor in an amount effective to form, when activated, a chlorine dioxide-containing composition including a contact lens disinfecting amount of chlorine dioxide. A polyanionic component, preferably a water soluble polyanionic component, is included in the composition in an amount effective to inhibit the formation of proteinaceous deposit material on a contact lens immersed in the chlorine dioxide-containing composition. Thus, effective contact lens disinfection is achieved while, at the same time, reducing the risk of forming proteinaceous deposit material on the contact lens during the disinfecting processing.Type: GrantFiled: December 12, 1994Date of Patent: July 15, 1997Assignee: AllerganInventors: John Y. Park, Lin Peng, Anthony J. Dziabo
-
Patent number: 5578240Abstract: A composition and method useful to quickly and effectively indicate whether a functional component such as catalase has been added to a clear solution such as a hydrogen peroxide solution involves compounding with the functional component an effective amount of vitamin B-12 such that when the compounded composition is added to the clear solution, the clear solution turns rose colored. By observing the rose color, the user can determine that the functional component has been added to the clear solution.Type: GrantFiled: April 14, 1994Date of Patent: November 26, 1996Assignee: Allergan, Inc.Inventors: John Y. Park, James N. Cook, Anthony J. Dziabo, Jr.
-
Patent number: 5336434Abstract: Methods for disinfecting a lens are disclosed. In one embodiment, the methods comprise contacting a lens, e.g., a contact lens, to be disinfected with a liquid medium containing stabilized chlorine dioxide and an activator component selected from chlorine dioxide reducing agents and mixtures thereof to effect formation of chlorine dioxide from the stabilized chlorine dioxide, thereby disinfecting the lens. Compositions and apparatus useful in the above-noted methods are also disclosed.Type: GrantFiled: November 10, 1992Date of Patent: August 9, 1994Assignee: Allergan, Inc.Inventors: John Y. Park, Paul S. Ripley, Anthony J. Dziabo
-
Patent number: 5330752Abstract: Compositions and methods useful in destroying residual oxidative disinfectant, e.g., used to disinfect a contact lens, are disclosed. In one embodiment, the method comprises contacting an oxidative disinfectant-containing liquid medium with a material selected from glutathione, oxidized glutathione and mixtures thereof, and a co-factor selected from nicotinamide adenine dinucleotide phosphate, nicotinamide adenine dinucleotide and mixtures thereof in the presence of glutathione reductase in an amount effective to promote the oxidation of the co-factor.Type: GrantFiled: September 21, 1993Date of Patent: July 19, 1994Assignee: Allergan, Inc.Inventors: John Y. Park, James N. Cook
-
Patent number: 5281353Abstract: Compositions and methods useful in destroying residual oxidative disinfectant, e.g., used to disinfect a contact lens, are disclosed. In one embodiment, the method comprises contacting an oxidative disinfectant-containing liquid medium with a material selected from glutathione, oxidized glutathione and mixtures thereof, and a co-factor selected from nicotinamide adenine dinucleotide phosphate, nicotinamide adenine dinucleotide and mixtures thereof in the presence of glutathione reductase in an amount effective to promote the oxidation of the co-factor.Type: GrantFiled: April 24, 1991Date of Patent: January 25, 1994Assignee: Allergan, Inc.Inventors: John Y. Park, James N. Cook
-
Patent number: 5230899Abstract: Liposome-forming materials containing a long chain aliphatic or aromatic-based acid or amine, hydrating agents and discrete amounts of water form gels which are useful drug delivery systems and spontaneously form highly stable liposomes in aqueous solution having very high capture efficiency.Type: GrantFiled: June 14, 1991Date of Patent: July 27, 1993Assignee: SmithKline Beecham CorporationInventors: John Y. Park, Shurl A. Thompson
-
Patent number: 5145644Abstract: Compostions, and method useful for making such compositions and for using such compositions, which are useful to destroy hydrogen peroxide in a liquid aqueous medium, such as that used to disinfect contact lenses, are disclosed. The composition comprises at least one item containing a hydrogen peroxide destroying component, e.g., catalase, effective when released in a liquid aqueous medium to destroy or cause the destruction of hydrogen peroxide present in the liquid aqueous medium, and a barrier coating located on the at least one item and acting to substantially prevent the release of the hydrogen peroxide destroying component for a period of time after the composition is initially contacted with a hydrogen peroxide-containing liquid aqueous medium. The barrier coating comprises a water soluble coating component, e.g.Type: GrantFiled: December 20, 1990Date of Patent: September 8, 1992Assignee: Allergan, Inc.Inventors: John Y. Park, James N. Cook